PMID- 11818714
OWN - NLM
STAT- MEDLINE
DCOM- 20020417
LR  - 20180213
IS  - 1660-8151 (Print)
IS  - 1660-8151 (Linking)
VI  - 90
IP  - 2
DP  - 2002 Feb
TI  - Prostate-specific antigen in hemodialysis patients and the influence of dialysis 
      in its levels.
PG  - 230-3
AB  - The determination of prostate-specific antigen (PSA) is a useful tool in the 
      diagnosis and follow-up of prostate cancer in males, but its diagnostic validity 
      is uncertain in hemodialysis patients. We prospectively evaluated PSA in male 
      hemodialysis patients as well as the influence of a single dialytic session on 
      its levels. We measured pre- and postdialysis total PSA (tPSA) in 63 hemodialysis 
      patients (mean age 68.44 +/- 11.16 years, range 33-86 years) who had received 
      dialysis with low flux membranes as well as in 729 normal subjects (mean age 
      63.22 +/- 16.85 years, range 28-92 years). We also measured pre- and postdialysis 
      hematocrit (Hct) in patients in order to estimate the degree of hemoconcentration 
      after the dialysis session. If any of the examined patients or subjects had 
      abnormal tPSA levels then free PSA (fPSA) and the f/tPSA ratio were additionally 
      measured. Patients had lower levels of tPSA compared with those of the subjects 
      (2.41 +/- 4.06 vs. 3.76 +/- 7.16 ng/ml, p < 0.05) while both of the two groups 
      had near equal prevalence of individuals with abnormal values of tPSA or f/tPSA 
      ratio (patients 12.69 and 7.93%, subjects 11.01 and 7.11%, respectively; 
      nonsignificant. Dialysis resulted in a 9.48% increase in mean tPSA levels (2.41 
      +/- 4.06 vs. 2.69 +/- 4.06 ng/ml, nonsignificant) and in a 10.09% increase in 
      mean Hct; the correlation between these increases was significant (r = 0.79, p < 
      0.001). In conclusion, our male hemodialysis patients had lower PSA levels 
      compared with the general population, while both groups of individuals had a 
      similar prevalence of abnormal values of tPSA and f/tPSA ratio. Dialysis with low 
      flux membranes does not eliminate PSA and its postdialysis increase is due to 
      hemoconcentration.
CI  - Copyright 2002 S. Karger AG, Basel
FAU - Tzanakis, Ioannis
AU  - Tzanakis I
AD  - Nephrological Department, General Hospital of Chania, Crete, Greece. 
      chaniahosp@hygeianet.gr
FAU - Kazoulis, Savas
AU  - Kazoulis S
FAU - Girousis, Nikolaos
AU  - Girousis N
FAU - Kagia, Stella
AU  - Kagia S
FAU - Spandidakis, Vlassis
AU  - Spandidakis V
FAU - Karefillakis, Nektarios
AU  - Karefillakis N
FAU - Georgila, Maria
AU  - Georgila M
FAU - Cristoulakis, Ionnis
AU  - Cristoulakis I
FAU - Hatzilias, Petros
AU  - Hatzilias P
FAU - Kallivretakis, Nikolaos
AU  - Kallivretakis N
LA  - eng
PT  - Journal Article
PL  - Switzerland
TA  - Nephron
JT  - Nephron
JID - 0331777
RN  - EC 3.4.21.77 (Prostate-Specific Antigen)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Humans
MH  - Kidney Failure, Chronic/*blood/*therapy
MH  - Male
MH  - Middle Aged
MH  - Prostate-Specific Antigen/*blood
MH  - Prostatic Neoplasms/blood/diagnosis
MH  - *Renal Dialysis
EDAT- 2002/01/31 10:00
MHDA- 2002/04/18 10:01
CRDT- 2002/01/31 10:00
PHST- 2002/01/31 10:00 [pubmed]
PHST- 2002/04/18 10:01 [medline]
PHST- 2002/01/31 10:00 [entrez]
AID - nef90230 [pii]
AID - 10.1159/000049051 [doi]
PST - ppublish
SO  - Nephron. 2002 Feb;90(2):230-3. doi: 10.1159/000049051.